JUM Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hutter, J. C.
Right arrow Articles by Dittrich, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hutter, J. C.
Right arrow Articles by Dittrich, H. C.

Journal of Ultrasound in Medicine, Vol 18, Issue 1 1-11, Copyright © 1999 by American Institute of Ultrasound in Medicine

CLINICAL TRIAL

Physiologically based pharmacokinetic model for fluorocarbon elimination after the administration of an octafluoropropane-albumin microsphere sonographic contrast agent

J. C. Hutter, H. M. Luu, P. M. Mehlhaff, A. L. Killam and H. C. Dittrich
Center for Devices and Radiological Health, United States Food and Drug Administration, Rockville, MD 20852, USA.

A physiologically based pharmacokinetic model was developed to evaluate the kinetics of one of the newest sonographic contrast agents available, FS069 or Optison. This material consists of octafluoropropane gas encapsulated in proteinaceous microspheres, injected intravenously for use as a myocardial contrast agent in humans. This model has six compartments: two lung compartments (alveolar and dead volume), and compartments for the heart, slowly perfused tissue, richly perfused tissue, and gastrointestinal tract. The model was developed to determine the distribution and excretion of the octafluoropropane in the body. Despite the high affinity of octafluoropropane for tissue, the model predicted that nearly 100% of the material would be exhaled from the lungs within 6 min. The model verified the results of a phase I clinical trial with 10 healthy subjects. Ventilation rate was found to play a critical role in the complete excretion of this contrast agent. The physiologically based pharmacokinetic model was a useful tool for evaluating the safety of FS069. This model can be used a basis for developing similar models for other types of contrast agents.


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
G. Mychaskiw II, A. E. Badr, R. Tibbs, B. R. Clower, and J. H. Zhang
Optison (FS069) Disrupts the Blood-Brain Barrier in Rats
Anesth. Analg., October 1, 2000; 91(4): 798 - 803.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Institute of Ultrasound in Medicine.